**These articles have been corrected:** The proper images for Figure 3 and Figure 4 are shown below. The authors declare that these corrections do not change the results or conclusions of this paper.
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![AMPK activation mediated dasatinib-induced ER stress and EGFR degradation.\
(A) The effect of dasatinib on AMPK activation. Cells were treated with dasatinib (1uM) for indicated intervals. The expression of p-AMPK and AMPK was evaluated. (B) The effect of AMPK knockdown on dasatinib-induced EGFR degradation and ER stress. Cells were treated with control or AMPK siRNA and then with dasatinib for 24 hours. (C) The effect of AMPK activation on dasatinib-induced EGFR degradation. Cells were treated with dasatinib with or without AICAR (10uM) for 24 hours. The expression of EGFR p-eIF2α, and AMPK was evaluated. (D) The correlation between p-AMPK and EGFR expression. *Left*, the expression of EGFR, p-AMPK, and AMPK in HNSCC cells. *Right*, the correlation of p-AMPK and EGFR expression in resected human specimens. Pearson's correlation coefficient=0.659; \*, p\<0.01.](oncotarget-10-5724-g001){#F1}

![Dasatinib induced cellular ATP decrease and PDK4 up-regulation.\
(A,B) The effect of 6-hr or 18-hr dasatinib (1uM) on cellular ATP (A) and glucose (B) levels. \*, p\<0.05. (C) The expression of PDK4 and p-Erk in HNSCC cells treated with dasatinib (1uM) for indicated intervals.](oncotarget-10-5724-g002){#F2}
